Acorda Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2003
Net Income	-252.85	-65.92	-103.95	-99.59	-272.97	Upgrade
Depreciation & Amortization	31.6	32.81	33.95	41.3	34.57	Upgrade
Share-Based Compensation	0.48	1.49	3	8.1	14.25	Upgrade
Other Operating Activities	206.79	10.69	25.66	-10.81	95.98	Upgrade
Operating Cash Flow	-13.98	-20.92	-41.35	-61.01	-128.17	Upgrade
Capital Expenditures	-0.26	-0.14	-0.17	-4.39	-90.43	Upgrade
Change in Investments	0	0	73.97	63.75	89.92	Upgrade
Other Investing Activities	-	-	-0.03	-	-	Upgrade
Investing Cash Flow	-0.26	-0.14	73.78	59.36	-0.51	Upgrade
Share Issuance / Repurchase	0	0	0	0	-0.07	Upgrade
Debt Issued / Paid	0	0	-69.66	-1.67	-60.48	Upgrade
Financing Cash Flow	0	0	-69.66	-1.67	-60.55	Upgrade
Exchange Rate Effect	0.19	0.51	-0.45	1.02	0.06	Upgrade
Net Cash Flow	-14.06	-20.55	-37.67	-2.3	-189.16	Upgrade
Free Cash Flow	-14.25	-21.06	-41.51	-65.4	-218.59	Upgrade
Free Cash Flow Margin	-12.11%	-17.76%	-32.16%	-42.75%	-113.61%	Upgrade
Free Cash Flow Per Share	-11.47	-20.83	-78.17	-161.79	-551.51	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).